NPRL2 gene therapy induces robust antitumor immunity and overcome anti-PD1 resistance through augmenting antigen-presentation and cytotoxic T cells activation in KRAS/STK11 mutant NSCLC in humanized mouse model.
An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.
Structure-based designed chalcone and pyrazoline derivatives inhibited the ELF3-MED23 protein-protein interaction, leading to HER2 downregulation and retardation of tumor growth in HER2-positive gastric cancer.